CA
NZ
UK
AU
IND
US
…
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Milestone Pharmaceuticals Inc (MIST) is a Nasdaq-listed company engaged in developing therapeutic candidates, according to its public filings. Long-term growth may be driven by successful clinical development, licensing or partnership deals, and eventual commercialization of approved products, which could support pipeline expansion and revenue potential.
Primary investment risks include clinical and regulatory failure, the need for additional financing with potential dilution, limited operating history and commercial infrastructure, and competition from larger biotechnology and pharmaceutical companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -63.40M | -41.52M | -59.69M | -58.39M | -42.85M |
| Net income | -63.06M | -41.52M | -59.69M | -57.13M | -42.63M |
| Selling general administrative | 17.27M | 16.74M | 15.93M | 15.72M | 12.40M |
| Selling and marketing expenses | - | 11.00M | 15.11M | 9.10M | 7.00M |
| Gross profit | 1.43M | -0.65M | 1.00M | 5.00M | 15.00M |
| Reconciled depreciation | 0.11M | 0.10M | 0.08M | 0.09M | 0.09M |
| Ebit | -59.56M | -37.94M | -57.13M | -59.73M | -43.07M |
| Ebitda | -59.45M | -37.83M | -57.04M | -59.64M | -42.98M |
| Depreciation and amortization | 0.11M | 0.10M | 0.09M | 0.09M | 0.09M |
| Non operating income net other | - | - | - | - | 0.22M |
| Operating income | -62.48M | -42.10M | -61.10M | -59.64M | -43.07M |
| Other operating expenses | 64.03M | 42.10M | 62.10M | 64.64M | 58.07M |
| Interest expense | 3.84M | 3.58M | 2.55M | -1.25M | 0.22M |
| Tax provision | - | - | - | - | 0.00M |
| Interest income | 2.92M | 4.16M | 3.50M | 1.25M | 0.22M |
| Net interest income | -0.92M | 0.58M | 1.81M | 1.25M | 0.22M |
| Income tax expense | -0.34M | -0.26M | -0.31M | -1.25M | -0.22M |
| Total revenue | 1.55M | 0.00M | 1.00M | 5.00M | 15.00M |
| Total operating expenses | 63.92M | 42.10M | 62.10M | 64.64M | 58.07M |
| Cost of revenue | 0.11M | 0.65M | 0.60M | - | - |
| Total other income expense net | -0.92M | 0.58M | 1.41M | 1.25M | 0.22M |
| Net income from continuing ops | -63.06M | -41.52M | -59.25M | -58.39M | -42.85M |
| Net income applicable to common shares | - | - | - | -58.39M | -42.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 113.56M | 75.50M | 75.23M | 74.48M | 119.85M |
| Other current assets | 1.80M | 1.84M | 3.18M | 6.34M | 4.66M |
| Total liab | 71.79M | 62.35M | 58.45M | 8.13M | 7.25M |
| Total stockholder equity | 41.77M | 13.15M | 16.77M | 66.35M | 112.60M |
| Other current liab | 7.69M | 5.62M | 2.70M | 3.38M | 2.17M |
| Common stock | 352.62M | 288.05M | 260.50M | 273.90M | 251.90M |
| Capital stock | 352.62M | 288.05M | 260.50M | 273.90M | 251.90M |
| Retained earnings | -430.60M | -367.55M | -326.03M | -266.34M | -206.32M |
| Cash | 73.05M | 25.31M | 13.76M | 7.64M | 114.14M |
| Total current liabilities | 13.98M | 8.13M | 7.23M | 6.14M | 6.78M |
| Net debt | -14.67M | 29.48M | 38.02M | -5.14M | -113.44M |
| Short term debt | 0.65M | 0.57M | 0.55M | 0.49M | 0.22M |
| Short long term debt total | 58.38M | 54.80M | 51.77M | 2.49M | 0.70M |
| Other stockholder equity | 64.10M | 39.57M | 33.83M | 58.79M | 68.65M |
| Property plant equipment | - | - | - | 2.68M | 0.21M |
| Total current assets | 111.92M | 73.93M | 73.03M | 71.80M | 118.92M |
| Net tangible assets | - | - | - | 66.35M | 112.60M |
| Short term investments | 32.91M | 44.38M | 52.24M | 56.95M | - |
| Net receivables | 3.51M | 2.39M | 3.85M | 1.21M | 0.48M |
| Long term debt | 57.19M | 53.35M | 49.77M | - | - |
| Inventory | 0.65M | 0.00M | - | -0.33M | -0.36M |
| Accounts payable | 5.64M | 1.93M | 3.98M | 2.26M | 4.38M |
| Accumulated other comprehensive income | 55.65M | 53.08M | 48.46M | - | -1.63M |
| Common stock total equity | - | - | - | - | 251.90M |
| Retained earnings total equity | - | - | - | - | -206.32M |
| Non currrent assets other | - | - | - | - | 0.71M |
| Non current assets total | 1.64M | 1.57M | 2.19M | 2.68M | 0.93M |
| Capital lease obligations | 1.19M | 1.45M | 2.00M | 2.49M | 0.70M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 11.55M | 8.28M | -25.93M | -57.12M | 70.00M |
| Change to liabilities | - | - | - | -0.91M | 0.64M |
| Total cashflows from investing activities | 11.25M | 8.28M | 4.76M | -57.12M | 70.00M |
| Net borrowings | - | 0.00M | 50.00M | - | - |
| Total cash from financing activities | 85.53M | 32.12M | 47.79M | 3.09M | 5.05M |
| Change to operating activities | - | - | - | -1.60M | 1.52M |
| Net income | -63.06M | -41.52M | -59.69M | -58.39M | -42.85M |
| Change in cash | 47.73M | 11.55M | 6.12M | -106.50M | 41.83M |
| Begin period cash flow | 25.31M | 13.76M | 7.64M | 114.14M | 72.31M |
| End period cash flow | 73.05M | 25.31M | 13.76M | 7.64M | 114.14M |
| Total cash from operating activities | -49.04M | -28.85M | -46.42M | -52.47M | -33.22M |
| Issuance of capital stock | 51.01M | 27.26M | -0.01M | 2.63M | 0.00M |
| Depreciation | 0.11M | 0.10M | 0.09M | 0.09M | 0.09M |
| Other cashflows from investing activities | -83.22M | -113.59M | - | - | - |
| Change to inventory | -0.65M | 0.00M | - | - | - |
| Change to account receivables | -1.12M | 1.46M | -2.64M | - | 0.10M |
| Sale purchase of stock | - | - | - | - | 0.12M |
| Other cashflows from financing activities | 85.53M | 4.86M | -2.21M | 0.46M | 5.05M |
| Change to netincome | - | - | - | - | 7.28M |
| Capital expenditures | 0.30M | 0.03M | 0.11M | 0.27M | 0.00M |
| Change receivables | - | - | - | - | 0.10M |
| Cash flows other operating | - | - | - | - | 1.52M |
| Cash and cash equivalents changes | - | - | - | - | 41.83M |
| Change in working capital | 2.68M | 3.66M | 1.24M | -3.26M | 2.26M |
| Stock based compensation | 7.46M | 5.78M | 9.53M | 9.05M | 7.28M |
| Other non cash items | 3.76M | 3.13M | 2.39M | 0.04M | 32.64M |
| Free cash flow | -49.34M | -28.88M | -46.54M | -52.74M | -33.22M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MIST Milestone Pharmaceuticals Inc |
0.04 5.30% |
0.76 | - | - | 49.29 | 6.56 | 3.82 | -1.43 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
514 336 0444
38
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph G. Oliveto M.B.A. | CEO, Pres & Director | 1968 |
| Mr. Amit Hasija | CFO & Exec. VP of Corp. Devel. | 1973 |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board | 1962 |
| Mr. Jeff Nelson | Chief Operating Officer | NA |
| Mr. Roshan Girglani | VP of Marketing | NA |
| Ms. Kimberly Sheehan | VP of HR | NA |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board | 1956 |
| Dr. Guy Rousseau | SVP of Regulatory Affairs and Quality Management | NA |
| Mr. Lorenz Muller | Chief Commercial Officer | 1964 |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...